An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants
暂无分享,去创建一个
J. Dumortier | A. Heng | N. Kamar | L. Frimat | P. Grimbert | S. Fafi-Kremer | F. Saliba | C. Vigneau | P. Gatault | R. Snanoudj | A. Durrbach | E. Rondeau | D. Anglicheau | M. Hazzan | A. Sicard | E. Morelon | O. Thaunat | C. Mariat | G. Blancho | S. Dharancy | Y. Le Meur | O. Brugière | A. Thierry | B. Moulin | B. Barrou | N. Bouvier | J. Tourret | M. Tsimaratos | L. Sebbag | V. Moal | A. Hertig | M. Matignon | J. Augusto | C. Garrouste | C. Mousson | P. Malvezzi | M. Buchler | A. Roux | P. Westeel | P. Merville | D. Ducloux | M. Le Quintrec | J. Bamoulid | L. Couzi | S. Mussot | S. Caillard | É. Salame | A. Duveau | J. Rerolle | D. Bertrand | Maïté Jauréguy | J. Chemouny | C. Colosio | Nathalie Chavarot | L. Golbin | T. Legris | C. Masset | H. François | C. Grèze | E. Salamé | B. Schvartz | E. Epailly | Florentine Garaix-Gilardo | Marie C Morin | Henri Vacher Coponat | N. Chavarot | H. V. Coponat | Clarisse Grèze | Agnès Duveau
[1] F. Scolari,et al. Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience , 2020, American Journal of Transplantation.
[2] N. Sumrani,et al. COVID‐19 pneumonia in kidney transplant recipients: Focus on immunosuppression management , 2020, Transplant infectious disease : an official journal of the Transplantation Society.
[3] M. Betjes,et al. COVID‐19 in solid organ transplant recipients: a single‐center experience , 2020, Transplant international : official journal of the European Society for Organ Transplantation.
[4] U. Maggiore,et al. How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[5] Sumit Mohan,et al. Early Outcomes of Outpatient Management of Kidney Transplant Recipients with Coronavirus Disease 2019. , 2020, Clinical journal of the American Society of Nephrology : CJASN.
[6] J. Qu,et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial , 2020, BMJ.
[7] R. Schwartz,et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.
[8] S. Bae,et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19 , 2020, Clinical Microbiology and Infection.
[9] K. Davidson,et al. COVID-19 in kidney transplant recipients , 2020, American Journal of Transplantation.
[10] E. Akalin,et al. Covid-19 and Kidney Transplantation , 2020, The New England journal of medicine.
[11] N. Uriel,et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter , 2020, American Journal of Transplantation.
[12] S. Mohan. Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York. , 2020, Journal of the American Society of Nephrology : JASN.
[13] S. McAdoo,et al. COVID-19 and Calcineurin Inhibitors: Should They Get Left Out in the Storm? , 2020, Journal of the American Society of Nephrology : JASN.
[14] Bin Liu,et al. Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China , 2020, European Urology.
[15] Nathaniel Hupert,et al. Clinical Characteristics of Covid-19 in New York City , 2020, The New England journal of medicine.
[16] A. Gasbarrini,et al. Off‐label use of tocilizumab in patients with SARS‐CoV‐2 infection , 2020, Journal of medical virology.
[17] J. Aguado,et al. COVID-19 in solid organ transplant recipients: A single-center case series from Spain , 2020, American Journal of Transplantation.
[18] Binqing Fu,et al. Why tocilizumab could be an effective treatment for severe COVID-19? , 2020, Journal of Translational Medicine.
[19] J. Qu,et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial , 2020, medRxiv.
[20] W. Zhou,et al. Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients , 2020, American Journal of Transplantation.
[21] Sapna Shah,et al. COVID-19 infection in kidney transplant recipients , 2020, Kidney International.
[22] F. Scolari,et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia , 2020, Kidney International.
[23] S. Merler,et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.
[24] C. Eastin,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The Journal of Emergency Medicine.
[25] U. Maggiore,et al. COVID-19 in kidney transplant recipients , 2020, American Journal of Transplantation.
[26] Zhan Zhang,et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial , 2020, medRxiv.
[27] F. Diekmann,et al. Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? , 2020, American Journal of Transplantation.
[28] Sharukh Lokhandwala,et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. , 2020, JAMA.
[29] Yuan Wei,et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.
[30] Yu Shi,et al. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan , 2020, Critical Care.
[31] Hanxiong Guan,et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression , 2020, American Journal of Transplantation.
[32] P. Mehta,et al. COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.
[33] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[34] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[35] A. Gaber,et al. Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center , 2020, Transplantation.
[36] A. von Brunn,et al. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506 , 2012, Virus Research.
[37] M. V. van Hemert,et al. Cyclosporin A inhibits the replication of diverse coronaviruses. , 2011, The Journal of general virology.